Accelerator Award (AA) proposals ($1,200,000, four years) are the largest NETRF grants in terms of scope, length, and money. These proposals have usually three substantial aims that describe work requiring four years to complete. They might have several collaborators and are often multi-disciplinary or multi-institutional. They can be considered equivalent to an NIH RO1 grant.
An Accelerator Award totals $1,200,000 over four years. At least one Accelerator Award is awarded annually.
The Neuroendocrine Tumor Research Foundation (NETRF) seeks investigators and teams with the tools to study neuroendocrine cancers in innovative and transformative ways.
- Applicants must have a faculty appointment (assistant professor and above). Applicants must have the skills, knowledge, and resources necessary to carry out the proposed research.
- Applicants must have an MD, PhD, MD/PhD or equivalent degree.
- Candidates must demonstrate a commitment to continue with NET research and the potential for further development in this area.
- Prior research in this field is not a prerequisite; in fact, the Foundation wishes to encourage expert scientists to enter the field. Applicants must, however, demonstrate a plan for continuing their research in NETs beyond the award period.
- Eligible organizations include public or private institutions, such as universities, colleges, hospitals, and laboratories, both domestic and international. Grants will be paid in US dollars.
- Projects that bring together investigators from diverse scientific disciplines are highly encouraged. For team applications, one recipient principal investigator and recipient institution must be selected. International applications are welcome.
- Awardees, as a condition of acceptance, will be required to attend the annual NETRF Research Symposium. Up to $2,000 may be allocated from the grant to offset the recipient’s registration and attendance costs for the Symposium.
NETRF will recruit for Accelerator Award applications as part of our annual Request for Applications (RFA). Letters of Intent (LOI) are reviewed by the NETRF Board of Scientific Advisors, with applicants invited to submit full applications based on the quality of the project, support from the applicant’s institution, budget, and potential of the research to advance the field.
Grant recipients are required to submit biannual reports detailing scientific progress, research milestones achieved, and financial expenditures related to the project. These reports are reviewed by NETRF’s Scientific Review and Grants Administration team to ensure that funds are being properly spent and that sufficient progress is made throughout the grant term. Continued funding is contingent upon review of progress and achievement of relevant milestones.
The latest in NET News
NETRF’s Director of Research John Kanki, PhD, provides an update on the status of ongoing NETRF-funded research studies during COVID-19.
NETRF reports progress in the development of neuroendocrine tumor cell lines to help eliminate a decades-old obstacle in laboratory research. To stimulate progress in NET cell lines, NETRF established a Cell Line Prize, funded cell line research, and launched a collaboration with a nationally known research institute. Each of these initiatives has succeeded in establishing NET cell lines.
Research to Advance Neuroendocrine Tumor Treatment The Neuroendocrine Tumor Research Foundation (NETRF) today announced $3.5